Oncolytic Immunotherapy Using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients

Grant

Date/time Interval

  • December 21, 2020 - December 20, 2025
  • Total Award Amount

  • 0.00
  • Direct Costs

  • 0.00
  • Sponsor Award Id

  • Contributor

  • Gary Cutter   Investigator  
  • George Gillespie   Investigator  
  • Inmaculada Aban   Investigator  
  • James Markert M.D., M.P.H.   Principal Investigator  
  • Jianmei Leavenworth Ph.D.   Investigator  
  • Louis Nabors M.D.   Investigator